Homozygous Familial Hypercholesterolemia: Improving Outcomes and the Patient Perspective
November 8, 2023
November 8, 2024
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventative Cardiology (ASPC).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
The educational design of this activity addresses the needs of cardiologists, endocrinologists, and primary care practitioners.
Establishing an early diagnosis of homozygous familial hypercholesterolemia (HoFH) is important to ensure prompt treatment, lower low-density lipoprotein cholesterol, and reduce risk of progressive atherosclerotic cardiovascular disease. However, many patients remain undiagnosed until advanced cardiovascular disease is present. HoFH is also a difficult-to-treat disorder, with most patients requiring multiple lipid-lowering therapies and many not achieving target LDL-C levels.
Join a cardiologist and a lipidologist to review recommended screening and diagnostic techniques for HoFH. Panelists will discuss new therapies and associated indications, including the selection and sequencing of HoFH treatments. Also, in order to align HCP and patient perspectives and goals, experts will share strategies to improve clinician-patient communication, while reacting to role-play videos of patients and clinicians discussing HoFH in point-of-care settings.
After completing this activity, the participant should be better able to:
- Describe endorsed screening approaches and diagnostic criteria for HoFH
- Characterize approaches for incorporating therapies for HoFH into a patient-centered management plan
- Elucidate the mechanisms of action and efficacy and safety data for newer agents for HoFH, including emerging indications
Erin D. Michos, MD, MHS
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Paul V. Kramer Endowed Chair in Cardiovascular Disease Prevention
Director, Seinsheimer Cardiovascular Health Program
Trustee, American College of Cardiology
The Medical University of South Carolina
Kathleen H. Byrne, MSN, CRNP, FNLA, CLS, FPCNA
Cardiovascular Nurse Practitioner
Clinical Lipids Specialist
Johns Hopkins Medical Institutions
Interview Participant - Individual with HoFH
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Accreditation Statement
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 1 hour to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at [email protected].
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”